Pharma BD Deal Intelligence
AstraZeneca PLC / Ardea Biosciences, Inc.
2012 · Acquisition/Merger · $1.3B · Complete
Announcement Sentiment
79
Strongly positive
AstraZeneca acquired Ardea Biosciences at $32/share cash, total ~$1.26B (50% premium to 1-month VWAP). Added Phase 3 lesinurad for gout plus next-gen URAT1 inhibitor RDEA3170 (Phase 1).
Did it work? Outcome assessment
Strategic verdict
Failed to Achieve
Financial impact
Impaired/Written Down
Pipeline outcome
Assets Terminated
Assessment window: 10yr post-close.
Key facts
- Announced Apr 23, 2012
- Closed Jun 19, 2012
- Deal value $1.3B
- Deal type Acquisition/Merger
- Therapeutic area Gout (hyperuricemia)
- Indications Gout (hyperuricemia)
- Key assets Lesinurad (Zurampic)
- Mechanism Selective uric acid reabsorption inhibitor (URAT1)
See the full interactive analysis, sources & comparables →
← Browse all deals ·
How we score deals